128
Participants
Start Date
March 31, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
April 30, 2012
icotinib
Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
Cancer Hospital, Chinese Academy of Medical Science, Beijing
Peking Union Medical College Hospital, Beijing
Bejing Cancer Hospital, Beijing
307 Hospital of PLA, Beijing
Beijing Chest Hospital, Beijing
Shanghai Pulmonary Hospital, Shanghai
Jiangsu Cancer Hospital, Nanjing
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Third Affiliated Hospital, Third Military Medical University, Chongqing
Sun yat-sen Univerisity Cancer Center, Guanzhou
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY